Core Points - The company held its second extraordinary general meeting on September 15, 2025, where multiple important resolutions were reviewed and passed with high votes [1] - The meeting utilized a combination of on-site and online voting, with a total of 105 shareholders and representatives present, representing 364,475,192 shares, which is 85.0922% of the total voting shares [1] Summary of Resolutions - Amendment of the Articles of Association: Total votes in favor were 364,364,792 shares, accounting for 99.9697% [2] - Revision of the Shareholders' Meeting Rules: Total votes in favor were 364,363,692 shares, accounting for 99.9694% [3] - Revision of the Board Meeting Rules: Total votes in favor were 364,360,392 shares, accounting for 99.9685% [3] - Revision of the Independent Director Work System: Total votes in favor were 364,361,692 shares, accounting for 99.9689% [3] - Revision of the External Guarantee Management System: Total votes in favor were 364,357,992 shares, accounting for 99.9678% [3] - Revision of the Related Party Transaction Management System: Total votes in favor were 364,368,592 shares, accounting for 99.9708% [3] - Revision of the External Investment Management System: Total votes in favor were 364,358,392 shares, accounting for 99.9680% [3] - Revision of the Controlling Shareholder and Actual Controller Behavior Norms: Total votes in favor were 364,371,492 shares, accounting for 99.9715% [3] - Revision of the Code of Conduct for Directors and Senior Management: Total votes in favor were 364,362,992 shares, accounting for 99.9692% [3] - Revision of the Fund Usage Management System: Total votes in favor were 364,359,092 shares, accounting for 99.9681% [3] - Revision of the Major Transaction Management System: Total votes in favor were 364,367,292 shares, accounting for 99.9704% [3] Abolishment of Supervisory Committee Regulations - The resolution to abolish the Supervisory Committee Meeting Rules was passed with total votes in favor of 364,373,192 shares, accounting for 99.9720% [4]

国浩律师(广州)事务所 关于汕头市超声仪器研究所股份有限公司 2025 年第二次临时股东会的法律意见 汕头市超声仪器研究所股份有限公司: 根据中国证券监督管理委员会发布的《上市公司股东会规则》(以下简称《股 东会规则》）的要求,国浩律师(广州)事务所(以下简称"本所")接受汕头市超 声仪器研究所股份有限公司(以下简称"超研股份")的委托,指派周姗姗、林嘉 豪律师(以下简称"本所律师")出席超研股份 2025 年第二次临时股东会(以下简 称"本次股东会")，对本次股东会的召集与召开程序、出席会议人员与召集人 的资格、表决程序与表决结果等重要事项出具法律意见。 本所及本所律师依据《中华人民共和国公司法》(以下简称《公司法》)、《律 师事务所从事证券法律业务管理办法》和《律师事务所证券法律业务执业规则(试 行)》等规定及本法律意见书出具日以前已经发生或者存在的事实,严格履行了 法定职责,遵循了勤勉尽责和诚实信用原则,进行了充分的核查验证,保证本法 律意见书所认定的事实真实、准确、完整，所发表的结论性意见合法、准确，不 存在虚假记载、误导性陈述或者重大遗漏，并承担相应法律责任。 一、本次股东会的召集与召开 律师(广州 ...

证券代码：301602 证券简称：超研股份 公告编号：2025-044 汕头市超声仪器研究所股份有限公司 2025年第二次临时股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 1、会议召开时间： （1）现场会议：2025年9月15日（星期一）15:00 （2）网络投票：通过深圳证券交易所交易系统进行网络投票的时间为2025 年9月15日9:15-9:25，9:30-11:30，13:00-15:00；通过深圳证券交易所互联网 投票系统投票的具体时间为2025年9月15日9:15-15:00期间的任意时间。 2、现场会议召开地点：广东省汕头市金砂路77号汕头市超声仪器研究所股 份有限公司1楼会议室。 3、召开方式：本次股东会采取现场投票与网络投票相结合的表决方式。 特别提示： 1、本次股东会未出现否决议案的情形； 2、本次股东会未涉及变更以往股东会已通过的决议。 一、会议召开和出席情况 （一） 召开情况 4、召集人：汕头市超声仪器研究所股份有限公司董事会 5、主持人：董事长李德来先生 6、会议的召开符合相关法律、行政法规、部门规章、规范性文件和公司 ...

Core Viewpoint - The company, Shantou Ultrasonic Instrument Research Institute Co., Ltd., is engaged in the research, development, production, and sales of medical imaging equipment and industrial non-destructive testing equipment, with a significant focus on the pet economy and smart medical technology [2][3]. Company Overview - Shantou Ultrasonic Instrument Research Institute Co., Ltd. was established on November 15, 1982, and was listed on January 22, 2025. It is recognized as a national key high-tech enterprise [7]. - The company's main business revenue composition includes: medical ultrasound (71.16%), industrial ultrasound (17.30%), accessories (5.72%), X-ray (4.56%), and others (1.26%) [7]. Financial Performance - For the first half of 2025, the company achieved operating revenue of 184 million yuan, representing a year-on-year growth of 15.00%. The net profit attributable to the parent company was 68.45 million yuan, with a year-on-year increase of 18.50% [8]. - As of June 30, 2025, the company had a total of 22,300 shareholders, a decrease of 16.65% from the previous period, while the average circulating shares per person increased by 19.98% [8]. Market Position and Trends - The company participated in the 97th WVC annual meeting, showcasing its innovative veterinary medical imaging achievements and engaging with industry experts [2]. - The company benefits from the depreciation of the RMB, with overseas revenue accounting for 55.26% of total revenue [2]. Stock Performance - On September 9, the company's stock price fell by 1.93%, with a trading volume of 71.26 million yuan and a turnover rate of 4.80%, resulting in a total market capitalization of 10.871 billion yuan [1].

Core Viewpoint - The company, Shantou Ultrasonic Instrument Research Institute Co., Ltd., is experiencing growth in the pet economy and smart medical sectors, benefiting from the depreciation of the RMB and being a newly listed stock under the registration system [2]. Company Overview - Shantou Ultrasonic Instrument Research Institute Co., Ltd. specializes in the research, development, production, and sales of medical imaging equipment and industrial non-destructive testing equipment [3][7]. - The company was established on November 15, 1982, and was listed on January 22, 2025 [3][7]. - The main business revenue composition includes: medical ultrasound 71.16%, industrial ultrasound 17.30%, accessories 5.72%, X-ray 4.56%, and others 1.26% [7]. Financial Performance - For the first half of 2025, the company achieved operating revenue of 184 million yuan, a year-on-year increase of 15.00%, and a net profit attributable to shareholders of 68.45 million yuan, up 18.50% year-on-year [8]. - As of June 30, 2025, the company had a total of 22,300 shareholders, a decrease of 16.65% from the previous period, with an average of 2,456 circulating shares per person, an increase of 19.98% [8]. Market Position and Trends - The company participated in the 97th WVC annual conference, showcasing innovations in veterinary medical imaging for pets, horses, and livestock, and engaging with industry experts [2]. - The company’s overseas revenue accounted for 55.26% of total revenue, benefiting from the depreciation of the RMB [2]. Shareholder Composition - As of June 30, 2025, the largest circulating shareholder is Huabao Zhongzheng Medical ETF, holding 1.9127 million shares, followed by Southern Zhongzheng 1000 ETF with 514,500 shares [9].

Core Viewpoint - The company, Shantou Ultrasonic Instrument Research Institute Co., Ltd., specializes in the research, development, production, and sales of medical imaging equipment and industrial non-destructive testing equipment, with a significant focus on the pet economy and smart medical technology [2][3][7]. Company Overview - Shantou Ultrasonic Instrument Research Institute Co., Ltd. was established on November 15, 1982, and went public on January 22, 2025. It is recognized as a national key high-tech enterprise [7]. - The company's main business revenue composition includes: medical ultrasound (71.16%), industrial ultrasound (17.30%), accessories (5.72%), X-ray (4.56%), and others (1.26%) [7]. Financial Performance - For the first half of 2025, the company achieved a revenue of 184 million yuan, representing a year-on-year growth of 15.00%. The net profit attributable to the parent company was 68.45 million yuan, with a year-on-year increase of 18.50% [8]. - As of June 30, 2025, the company had a total of 22,300 shareholders, a decrease of 16.65% from the previous period, while the average circulating shares per person increased by 19.98% [8]. Market Position and Trends - The company benefits from the depreciation of the RMB, with overseas revenue accounting for 55.26% of total revenue [3]. - The company is involved in various concept sectors, including nuclear power, medical devices, smart healthcare, and newly listed stocks [7]. Recent Developments - The company participated in the 97th WVC Annual Conference from March 3 to 5, 2025, showcasing its innovative veterinary medical imaging achievements and engaging with industry experts [2]. - The company has developed a "Hongyun" system for portable ultrasound and DR devices, enabling remote image transmission and online diagnostic guidance through its "Mali Doctor" platform [2][3]. Stock Performance - On September 4, 2025, the company's stock price fell by 1.18%, with a trading volume of 84.1682 million yuan and a turnover rate of 5.71%, resulting in a total market capitalization of 10.738 billion yuan [1]. - The average trading cost of the stock is 27.20 yuan, with the current price approaching a resistance level of 25.49 yuan, indicating potential for upward movement if this level is breached [6].

Core Viewpoint - The company, Shantou Ultrasonic Instrument Research Institute Co., Ltd., is engaged in the research, development, production, and sales of medical imaging equipment and industrial non-destructive testing equipment, benefiting from the pet economy and the depreciation of the RMB [2][3]. Group 1: Company Overview - Shantou Ultrasonic Instrument Research Institute Co., Ltd. was established on November 15, 1982, and was listed on January 22, 2025. It is a national key high-tech enterprise [7]. - The company's main business revenue composition includes: medical ultrasound 71.16%, industrial ultrasound 17.30%, accessories 5.72%, X-ray 4.56%, and others 1.26% [7]. - The company has a significant overseas revenue share of 55.26%, benefiting from the depreciation of the RMB [3]. Group 2: Financial Performance - For the period from January to June 2025, the company achieved operating revenue of 184 million yuan, a year-on-year increase of 15.00%, and a net profit attributable to shareholders of 68.45 million yuan, a year-on-year increase of 18.50% [8]. - The company has distributed a total of 43.69 million yuan in dividends since its A-share listing [9]. Group 3: Market Activity - On September 1, the company's stock rose by 0.69%, with a trading volume of 95.83 million yuan and a turnover rate of 6.26%, resulting in a total market capitalization of 11.27 billion yuan [1]. - The stock has seen a net outflow of 205,000 yuan from major funds today, with a continuous reduction in major fund holdings over the past three days [4][5].

Group 1 - The company announced that its second supervisory board meeting approved multiple proposals, including the "2025 Semi-Annual Report" and its summary [2]

Group 1 - The core point of the article is that Chao Yan Co., Ltd. announced the approval of multiple proposals, including the revision of the company's articles of association, during the ninth meeting of its second board of directors [2] Group 2 - The announcement was made on the evening of August 27 [2] - The meeting involved significant corporate governance decisions that may impact the company's operational framework [2] - The specific details of the revised articles of association were not disclosed in the announcement [2]

Core Viewpoint - The company announced the appointment of new senior management personnel to support its operational development needs [1] Group 1: Management Appointments - The company held its second board meeting on August 26, 2025, where it approved the appointment of new senior management [1] - Zheng Yanna and Li Bin were appointed as executive vice presidents, while Li Bohan and Lin Jinhao were appointed as vice presidents [1] - The term for these appointments will last until the end of the current board's term [1]